Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
25,125
archived clinical trials in
Diabetes

A Study of LY2605541 in Participants With Type 1 Diabetes Mellitus
A Comparison of LY2605541 Once Daily at a Fixed Time With LY2605541 Variable Time of Dosing in Participants With Type 1 Diabetes Mellitus: An Open Label, Randomized, Crossover Study
Status: Enrolling
Updated:  3/17/2018
Clinical Research Facility
mi
from
Chattanooga, TN
A Study of LY2605541 in Participants With Type 1 Diabetes Mellitus
A Comparison of LY2605541 Once Daily at a Fixed Time With LY2605541 Variable Time of Dosing in Participants With Type 1 Diabetes Mellitus: An Open Label, Randomized, Crossover Study
Status: Enrolling
Updated: 3/17/2018
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
A Study of LY2605541 in Participants With Type 1 Diabetes Mellitus
A Comparison of LY2605541 Once Daily at a Fixed Time With LY2605541 Variable Time of Dosing in Participants With Type 1 Diabetes Mellitus: An Open Label, Randomized, Crossover Study
Status: Enrolling
Updated:  3/17/2018
Clinical Research Facility
mi
from
Austin, TX
A Study of LY2605541 in Participants With Type 1 Diabetes Mellitus
A Comparison of LY2605541 Once Daily at a Fixed Time With LY2605541 Variable Time of Dosing in Participants With Type 1 Diabetes Mellitus: An Open Label, Randomized, Crossover Study
Status: Enrolling
Updated: 3/17/2018
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
A Study of LY2605541 in Participants With Type 1 Diabetes Mellitus
A Comparison of LY2605541 Once Daily at a Fixed Time With LY2605541 Variable Time of Dosing in Participants With Type 1 Diabetes Mellitus: An Open Label, Randomized, Crossover Study
Status: Enrolling
Updated:  3/17/2018
Clinical Research Facility
mi
from
Dallas, TX
A Study of LY2605541 in Participants With Type 1 Diabetes Mellitus
A Comparison of LY2605541 Once Daily at a Fixed Time With LY2605541 Variable Time of Dosing in Participants With Type 1 Diabetes Mellitus: An Open Label, Randomized, Crossover Study
Status: Enrolling
Updated: 3/17/2018
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of LY2605541 in Participants With Type 1 Diabetes Mellitus
A Comparison of LY2605541 Once Daily at a Fixed Time With LY2605541 Variable Time of Dosing in Participants With Type 1 Diabetes Mellitus: An Open Label, Randomized, Crossover Study
Status: Enrolling
Updated:  3/17/2018
Clinical Research Facility
mi
from
Round Rock, TX
A Study of LY2605541 in Participants With Type 1 Diabetes Mellitus
A Comparison of LY2605541 Once Daily at a Fixed Time With LY2605541 Variable Time of Dosing in Participants With Type 1 Diabetes Mellitus: An Open Label, Randomized, Crossover Study
Status: Enrolling
Updated: 3/17/2018
Clinical Research Facility
mi
from
Round Rock, TX
Click here to add this to my saved trials
A Study of LY2605541 in Participants With Type 1 Diabetes Mellitus
A Comparison of LY2605541 Once Daily at a Fixed Time With LY2605541 Variable Time of Dosing in Participants With Type 1 Diabetes Mellitus: An Open Label, Randomized, Crossover Study
Status: Enrolling
Updated:  3/17/2018
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
mi
from
Bayamon,
A Study of LY2605541 in Participants With Type 1 Diabetes Mellitus
A Comparison of LY2605541 Once Daily at a Fixed Time With LY2605541 Variable Time of Dosing in Participants With Type 1 Diabetes Mellitus: An Open Label, Randomized, Crossover Study
Status: Enrolling
Updated: 3/17/2018
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
mi
from
Bayamon,
Click here to add this to my saved trials
A Study to Compare the Effect of a Double Dose of Two Long-acting Insulin Therapies in Participants With Type 2 Diabetes
A Comparison of Pharmacodynamics When Receiving a Double Dose of Insulin Peglispro or Insulin Glargine in Patients With Type 2 Diabetes Mellitus: A Double-Blind, Crossover Design Study
Status: Enrolling
Updated:  3/17/2018
Profil Institute for Clinical Research
mi
from
Chula Vista, CA
A Study to Compare the Effect of a Double Dose of Two Long-acting Insulin Therapies in Participants With Type 2 Diabetes
A Comparison of Pharmacodynamics When Receiving a Double Dose of Insulin Peglispro or Insulin Glargine in Patients With Type 2 Diabetes Mellitus: A Double-Blind, Crossover Design Study
Status: Enrolling
Updated: 3/17/2018
Profil Institute for Clinical Research
mi
from
Chula Vista, CA
Click here to add this to my saved trials
A Study to Compare the Effect of a Double Dose of Two Long-acting Insulin Therapies in Participants With Type 2 Diabetes
A Comparison of Pharmacodynamics When Receiving a Double Dose of Insulin Peglispro or Insulin Glargine in Patients With Type 2 Diabetes Mellitus: A Double-Blind, Crossover Design Study
Status: Enrolling
Updated:  3/17/2018
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
mi
from
Mainz,
A Study to Compare the Effect of a Double Dose of Two Long-acting Insulin Therapies in Participants With Type 2 Diabetes
A Comparison of Pharmacodynamics When Receiving a Double Dose of Insulin Peglispro or Insulin Glargine in Patients With Type 2 Diabetes Mellitus: A Double-Blind, Crossover Design Study
Status: Enrolling
Updated: 3/17/2018
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
mi
from
Mainz,
Click here to add this to my saved trials
Gestational Diabetes Mellitus Trial (GDM)
A Randomized Clinical Trial of Treatment for Mild Gestational Diabetes Mellitus
Status: Enrolling
Updated:  3/19/2018
University of Alabama at Birmingham
mi
from
Birmingham, AL
Gestational Diabetes Mellitus Trial (GDM)
A Randomized Clinical Trial of Treatment for Mild Gestational Diabetes Mellitus
Status: Enrolling
Updated: 3/19/2018
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Gestational Diabetes Mellitus Trial (GDM)
A Randomized Clinical Trial of Treatment for Mild Gestational Diabetes Mellitus
Status: Enrolling
Updated:  3/19/2018
Northwestern University
mi
from
Chicago, IL
Gestational Diabetes Mellitus Trial (GDM)
A Randomized Clinical Trial of Treatment for Mild Gestational Diabetes Mellitus
Status: Enrolling
Updated: 3/19/2018
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Gestational Diabetes Mellitus Trial (GDM)
A Randomized Clinical Trial of Treatment for Mild Gestational Diabetes Mellitus
Status: Enrolling
Updated:  3/19/2018
Wayne State University - Hutzel Hospital
mi
from
Detroit, MI
Gestational Diabetes Mellitus Trial (GDM)
A Randomized Clinical Trial of Treatment for Mild Gestational Diabetes Mellitus
Status: Enrolling
Updated: 3/19/2018
Wayne State University - Hutzel Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Gestational Diabetes Mellitus Trial (GDM)
A Randomized Clinical Trial of Treatment for Mild Gestational Diabetes Mellitus
Status: Enrolling
Updated:  3/19/2018
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Gestational Diabetes Mellitus Trial (GDM)
A Randomized Clinical Trial of Treatment for Mild Gestational Diabetes Mellitus
Status: Enrolling
Updated: 3/19/2018
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Gestational Diabetes Mellitus Trial (GDM)
A Randomized Clinical Trial of Treatment for Mild Gestational Diabetes Mellitus
Status: Enrolling
Updated:  3/19/2018
Case Western Reserve Univ
mi
from
Cleveland, OH
Gestational Diabetes Mellitus Trial (GDM)
A Randomized Clinical Trial of Treatment for Mild Gestational Diabetes Mellitus
Status: Enrolling
Updated: 3/19/2018
Case Western Reserve Univ
mi
from
Cleveland, OH
Click here to add this to my saved trials
Gestational Diabetes Mellitus Trial (GDM)
A Randomized Clinical Trial of Treatment for Mild Gestational Diabetes Mellitus
Status: Enrolling
Updated:  3/19/2018
Ohio State University Hospital
mi
from
Columbus, OH
Gestational Diabetes Mellitus Trial (GDM)
A Randomized Clinical Trial of Treatment for Mild Gestational Diabetes Mellitus
Status: Enrolling
Updated: 3/19/2018
Ohio State University Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Gestational Diabetes Mellitus Trial (GDM)
A Randomized Clinical Trial of Treatment for Mild Gestational Diabetes Mellitus
Status: Enrolling
Updated:  3/19/2018
Oregon Health and Science University
mi
from
Portland, OR
Gestational Diabetes Mellitus Trial (GDM)
A Randomized Clinical Trial of Treatment for Mild Gestational Diabetes Mellitus
Status: Enrolling
Updated: 3/19/2018
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Gestational Diabetes Mellitus Trial (GDM)
A Randomized Clinical Trial of Treatment for Mild Gestational Diabetes Mellitus
Status: Enrolling
Updated:  3/19/2018
Drexel University
mi
from
Philadelphia, PA
Gestational Diabetes Mellitus Trial (GDM)
A Randomized Clinical Trial of Treatment for Mild Gestational Diabetes Mellitus
Status: Enrolling
Updated: 3/19/2018
Drexel University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Gestational Diabetes Mellitus Trial (GDM)
A Randomized Clinical Trial of Treatment for Mild Gestational Diabetes Mellitus
Status: Enrolling
Updated:  3/19/2018
University of Pittsburgh-Magee Womens Hospital
mi
from
Pittsburgh, PA
Gestational Diabetes Mellitus Trial (GDM)
A Randomized Clinical Trial of Treatment for Mild Gestational Diabetes Mellitus
Status: Enrolling
Updated: 3/19/2018
University of Pittsburgh-Magee Womens Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Gestational Diabetes Mellitus Trial (GDM)
A Randomized Clinical Trial of Treatment for Mild Gestational Diabetes Mellitus
Status: Enrolling
Updated:  3/19/2018
Brown University
mi
from
Providence, RI
Gestational Diabetes Mellitus Trial (GDM)
A Randomized Clinical Trial of Treatment for Mild Gestational Diabetes Mellitus
Status: Enrolling
Updated: 3/19/2018
Brown University
mi
from
Providence, RI
Click here to add this to my saved trials
Gestational Diabetes Mellitus Trial (GDM)
A Randomized Clinical Trial of Treatment for Mild Gestational Diabetes Mellitus
Status: Enrolling
Updated:  3/19/2018
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Gestational Diabetes Mellitus Trial (GDM)
A Randomized Clinical Trial of Treatment for Mild Gestational Diabetes Mellitus
Status: Enrolling
Updated: 3/19/2018
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Gestational Diabetes Mellitus Trial (GDM)
A Randomized Clinical Trial of Treatment for Mild Gestational Diabetes Mellitus
Status: Enrolling
Updated:  3/19/2018
University of Texas Medical Branch
mi
from
Galveston, TX
Gestational Diabetes Mellitus Trial (GDM)
A Randomized Clinical Trial of Treatment for Mild Gestational Diabetes Mellitus
Status: Enrolling
Updated: 3/19/2018
University of Texas Medical Branch
mi
from
Galveston, TX
Click here to add this to my saved trials
Gestational Diabetes Mellitus Trial (GDM)
A Randomized Clinical Trial of Treatment for Mild Gestational Diabetes Mellitus
Status: Enrolling
Updated:  3/19/2018
The University of Texas, Houston
mi
from
Houston, TX
Gestational Diabetes Mellitus Trial (GDM)
A Randomized Clinical Trial of Treatment for Mild Gestational Diabetes Mellitus
Status: Enrolling
Updated: 3/19/2018
The University of Texas, Houston
mi
from
Houston, TX
Click here to add this to my saved trials
Gestational Diabetes Mellitus Trial (GDM)
A Randomized Clinical Trial of Treatment for Mild Gestational Diabetes Mellitus
Status: Enrolling
Updated:  3/19/2018
University of Utah
mi
from
Salt Lake City, UT
Gestational Diabetes Mellitus Trial (GDM)
A Randomized Clinical Trial of Treatment for Mild Gestational Diabetes Mellitus
Status: Enrolling
Updated: 3/19/2018
University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Gestational Diabetes Mellitus Trial (GDM)
A Randomized Clinical Trial of Treatment for Mild Gestational Diabetes Mellitus
Status: Enrolling
Updated:  3/19/2018
Columbia University-St. Luke's Hospital
mi
from
New York, NY
Gestational Diabetes Mellitus Trial (GDM)
A Randomized Clinical Trial of Treatment for Mild Gestational Diabetes Mellitus
Status: Enrolling
Updated: 3/19/2018
Columbia University-St. Luke's Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Gestational Diabetes Mellitus Trial (GDM)
A Randomized Clinical Trial of Treatment for Mild Gestational Diabetes Mellitus
Status: Enrolling
Updated:  3/19/2018
Wake Forest University School of Medicine
mi
from
Winston-Salem, NC
Gestational Diabetes Mellitus Trial (GDM)
A Randomized Clinical Trial of Treatment for Mild Gestational Diabetes Mellitus
Status: Enrolling
Updated: 3/19/2018
Wake Forest University School of Medicine
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated:  3/19/2018
GSK Investigational Site
mi
from
Long Beach, CA
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated: 3/19/2018
GSK Investigational Site
mi
from
Long Beach, CA
Click here to add this to my saved trials
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated:  3/19/2018
GSK Investigational Site
mi
from
Pasadena, CA
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated: 3/19/2018
GSK Investigational Site
mi
from
Pasadena, CA
Click here to add this to my saved trials
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated:  3/19/2018
GSK Investigational Site
mi
from
Denver, CO
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated: 3/19/2018
GSK Investigational Site
mi
from
Denver, CO
Click here to add this to my saved trials
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated:  3/19/2018
GSK Investigational Site
mi
from
Hollywood, FL
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated: 3/19/2018
GSK Investigational Site
mi
from
Hollywood, FL
Click here to add this to my saved trials
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated:  3/19/2018
GSK Investigational Site
mi
from
Miami, FL
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated: 3/19/2018
GSK Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated:  3/19/2018
GSK Investigational Site
mi
from
Atlanta, GA
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated: 3/19/2018
GSK Investigational Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated:  3/19/2018
GSK Investigational Site
mi
from
Marietta, GA
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated: 3/19/2018
GSK Investigational Site
mi
from
Marietta, GA
Click here to add this to my saved trials
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated:  3/19/2018
GSK Investigational Site
mi
from
Honolulu, HI
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated: 3/19/2018
GSK Investigational Site
mi
from
Honolulu, HI
Click here to add this to my saved trials
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated:  3/19/2018
GSK Investigational Site
mi
from
Chicago, IL
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated: 3/19/2018
GSK Investigational Site
mi
from
Chicago, IL
Click here to add this to my saved trials
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated:  3/19/2018
GSK Investigational Site
mi
from
Indianapolis, IN
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated: 3/19/2018
GSK Investigational Site
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated:  3/19/2018
GSK Investigational Site
mi
from
Sunset, LA
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated: 3/19/2018
GSK Investigational Site
mi
from
Sunset, LA
Click here to add this to my saved trials
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated:  3/19/2018
GSK Investigational Site
mi
from
Oxon Hill, MD
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated: 3/19/2018
GSK Investigational Site
mi
from
Oxon Hill, MD
Click here to add this to my saved trials
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated:  3/19/2018
GSK Investigational Site
mi
from
Las Vegas, NV
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated: 3/19/2018
GSK Investigational Site
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated:  3/19/2018
GSK Investigational Site
mi
from
Pahrump, NV
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated: 3/19/2018
GSK Investigational Site
mi
from
Pahrump, NV
Click here to add this to my saved trials
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated:  3/19/2018
GSK Investigational Site
mi
from
Albany, NY
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated: 3/19/2018
GSK Investigational Site
mi
from
Albany, NY
Click here to add this to my saved trials
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated:  3/19/2018
GSK Investigational Site
mi
from
Buffalo, NY
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated: 3/19/2018
GSK Investigational Site
mi
from
Buffalo, NY
Click here to add this to my saved trials
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated:  3/19/2018
GSK Investigational Site
mi
from
Johnson City, NY
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated: 3/19/2018
GSK Investigational Site
mi
from
Johnson City, NY
Click here to add this to my saved trials
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated:  3/19/2018
GSK Investigational Site
mi
from
Rochester, NY
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated: 3/19/2018
GSK Investigational Site
mi
from
Rochester, NY
Click here to add this to my saved trials
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated:  3/19/2018
GSK Investigational Site
mi
from
Syracuse, NY
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated: 3/19/2018
GSK Investigational Site
mi
from
Syracuse, NY
Click here to add this to my saved trials
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated:  3/19/2018
GSK Investigational Site
mi
from
Durham, NC
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated: 3/19/2018
GSK Investigational Site
mi
from
Durham, NC
Click here to add this to my saved trials
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated:  3/19/2018
GSK Investigational Site
mi
from
Raleigh, NC
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated: 3/19/2018
GSK Investigational Site
mi
from
Raleigh, NC
Click here to add this to my saved trials
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated:  3/19/2018
GSK Investigational Site
mi
from
Cincinnati, OH
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated: 3/19/2018
GSK Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated:  3/19/2018
GSK Investigational Site
mi
from
Kettering, OH
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated: 3/19/2018
GSK Investigational Site
mi
from
Kettering, OH
Click here to add this to my saved trials
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated:  3/19/2018
GSK Investigational Site
mi
from
Sewickley, PA
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated: 3/19/2018
GSK Investigational Site
mi
from
Sewickley, PA
Click here to add this to my saved trials
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated:  3/19/2018
GSK Investigational Site
mi
from
Columbia, SC
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated: 3/19/2018
GSK Investigational Site
mi
from
Columbia, SC
Click here to add this to my saved trials
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated:  3/19/2018
GSK Investigational Site
mi
from
Kingsport, TN
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated: 3/19/2018
GSK Investigational Site
mi
from
Kingsport, TN
Click here to add this to my saved trials
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated:  3/19/2018
GSK Investigational Site
mi
from
Arlington, TX
A New Oral Treatment For Type II Diabetes Mellitus
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status: Enrolling
Updated: 3/19/2018
GSK Investigational Site
mi
from
Arlington, TX
Click here to add this to my saved trials